Background: Microlesion effect (MLE) is a commonly observed phenomenon after electrode insertion into the subthalamic nucleus (STN) for deep brain stimulation (DBS). Objectives: The aim of this study was to determine the presence of the MLE in the early postoperative period and the relationship between MLE and STN DBS. Methods: 74 patients with Parkinson’s disease were included in this study. Motor symptoms were evaluated preoperatively, within 48 h after electrode implantation and at 6 months with United Parkinson’s Disease Rating Scale part III (UPDRS-III). According to the improvement level with MLE, all participants were stratified into three groups: (1) less than 20%; (2) 20–40%, and (3) more than 40% in OFF medication states. The degree of improvement in UPDRS-III with DBS ON for each MLE group was assessed at the 6-month follow-up. Regression analysis was applied for the evaluation of the relationship between MLE and improvement with DBS ON. Results: Mean results in UPDRS-III with the MLE in ON and OFF medication states were 22.1 ± 10.5 and 42.1 ± 14 points, respectively. At the 6-month follow-up, with active stimulation, results tended to further ameliorate to 14.6 (59.4%) points in ON and 20.8 (55.3%) in OFF. Mean improvement in MLE groups were: 33.6% group 1, 47.5% group 2 and 61.4% group 3. Regression analysis revealed a positive correlation between the MLE and results at 6 months with DBS ON. Conclusion: Results proved the presence of MLE in the early postoperative period. Furthermore, a positive correlation between MLE and improvement degree with active stimulation was observed.

Keywords:
Deep brain stimulation, Microlesion effect, Parkinson’s disease, Subthalamic nucleus
1.
Benabid AL, Chabardes S, Mitrofanis J, Pollak P: Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol 2009;8:67–81.
2.
Benabid AL, Pollak P, Gross C, Hoffmann D, Benazzouz A, Gao DM, Laurent A, Gentil M, Perret J: Acute and long-term effects of subthalamic nucleus stimulation in Parkinson’s disease. Stereotact Funct Neurosurg 1994;62:76–84.
3.
Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL: Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 1998;339:1105–1111.
4.
Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P: Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 2003;349:1925–1934.
5.
Pahwa R, Wilkinson SB, Overman J, Lyons KE: Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow-up. J Neurosurg 2003;99:71–77.
6.
Deuschl G, Schade-Brittinger C, Krack P, et al: A randomised trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006;355:896–908.
7.
Mann JM, Foote KD, Garvan CW, et al: Brain penetration effects of microelectrodes and DBS leads in STN or GPI. J Neurol Neurosurg Psychiatry 2009;80:794–797.
8.
Maltête D, Chastan N, Derrey S, Debono B, Gérardin E, Lefaucheur R, Mihout B, Hannequin D: Microsubthalamotomy at day 3: screening for determinants. Mov Disord 2009;24:286–289.
9.
Maltête D, Derrey S, Chastan N, Debono B, Gérardin E, Fréger P, Mihout B, Menard JF, Hannequin D: Microsubthalamotomy: an immediate predictor of long-term subthalamic stimulation efficacy in Parkinson disease. Mov Disord 2008;23:1047–1050.
10.
Cersosimo MG, Raina GB, Benarroch EE, Piedimonte F, Alemán GG, Micheli FE: Micro lesion effect of the globus pallidus internus and outcome with deep brain stimulation in patients with Parkinson disease and dystonia. Mov Disord 2009;24:1488–1493.
11.
Granziera C, Pollo C, Russmann H, Staedler C, Ghika J, Villemure JG, Burkhard PR, Vingerhoets FJ: Sub-acute delayed failure of subthalamic DBS in Parkinson’s disease: the role of micro-lesion effect. Parkinsonism Relat Disord 2008;14:109–113.
12.
Defer GL, Widner H, Marié RM, Rémy P, Levivier M: Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 1999;14:572–584.
13.
Mandat T, Tykocki T, Koziara H, Koziorowski D, Brodacki B, Rola R, Bonicki W, Nauman P: Subthalamic deep brain stimulation for the treatment of Parkinson disease. Neurol Neurochir Pol 2011;45:32–36.
14.
Chang SY, Shon YM, Agnesi F, Lee KH: Microthalamotomy effect during deep brain stimulation: potential involvement of adenosine and glutamate efflux. Conf Proc IEEE Eng Med Biol Soc 2009:3294–3297.
15.
Nedergaard M: Direct signaling from astrocytes to neurons in cultures of mammalian brain cells. Science 1994;263:1768–1771.
16.
Bezzi P, Vesce S, Panzarasa P, Volterra A: Astrocytes as active participants of glutamatergic function and regulators of its homeostasis. Adv Exp Med Biol 1999;468:69–80.
17.
de la Fuente-Fernández R, Schulzer M, Stoessl AJ: The placebo effect in neurological disorders. Lancet Neurol 2002;i:85–91.
18.
de la Fuente-Fernández R, Schulzer M, Stoessl AJ: Placebo mechanisms and reward circuitry: clues from Parkinson’s disease. Biol Psychiatry 2004;56:67–71.
19.
de la Fuente-Fernández R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ: Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 2002;136:359–363.
20.
Mercado R, Constantoyannis C, Mandat T, Kumar A, Schulzer M, Stoessl AJ, Honey CR: Expectation and the placebo effect in Parkinson’s disease patients with subthalamic nucleus deep brain stimulation. Mov Disord 2006;21:1457–1461.
21.
de la Fuente-Fernández R: Uncovering the hidden placebo effect in deep-brain stimulation for Parkinson’s disease. Parkinsonism Relat Disord 2004;10:125–127.
22.
Bickel S, Alvarez L, Macias R, Pavon N, Leon M, Fernandez C, Houghton DJ, Salazar S, Rodríguez-Oroz MC, Juncos J, Guridi J, Delong M, Obeso JA, Litvan I: Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson’s disease. Parkinsonism Relat Disord 2010;16:535–539.
23.
Alvarez L, Macias R, Lopez G, Alvarez E, Pavon N, Rodriguez-Oroz MC, Juncos JL, Maragoto C, Guridi J, Litvan I, Tolosa ES, Koller W, Vitek J, DeLong MR, Obeso JA: Bilateral subthalamotomy in Parkinson’s disease: initial and long-term response. Brain 2005;128:570–583.
24.
Deuschl G, Herzog J, Kleiner-Fisman G, Kubu C, Lozano AM, Lyons KE, Rodriguez-Oroz MC, Tamma F, Tröster AI, Vitek JL, Volkmann J, Voon V: Deep brain stimulation: postoperative issues. Mov Disord 2006;21(suppl 14):S219–S237.
25.
Eckert T, Tang C, Eidelberg D: Assessment of the progression of Parkinson’s disease: a metabolic network approach. Lancet Neurol 2007;6:926–932.
26.
Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ, Eidelberg D: Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson’s disease. Proc Natl Acad Sci USA 2007;27:19559–19564.
27.
Pourfar M, Tang C, Lin T, Dhawan V, Kaplitt MG, Eidelberg D: Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. J Neurosurg 2009;110:1278–1282.
28.
Coubes P, Roubertie A, Vayssiere N, Hemm S, Echenne B: Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. Lancet 2000;355:2220–2221.
29.
Sudhyadhom A, Bova FJ, Foote KD, Rosado CA, Kirsch-Darrow L, Okun MS: Limbic, associative, and motor territories within the targets for deep brain stimulation: potential clinical implications. Curr Neurol Neurosci Rep 2007;7:278–289.
30.
Derrey S, Lefaucheur R, Chastan N, Gérardin E, Hannequin D, Desbordes M, Maltête D: Alleviation of off-period dystonia in Parkinson disease by a microlesion following subthalamic implantation. J Neurosurg 2010;112:1263–1266.
31.
Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson G, Benabid AL, Pollak P: Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002;59:932–934.
32.
Tsai ST, Lin SH, Chou YC, Pan YH, Hung HY, Li CW, Lin SZ, Chen SY: Prognostic factors of subthalamic stimulation in Parkinson’s disease: a comparative study between short- and long-term effects. Stereotact Funct Neurosurg 2009;87:241–248.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.